Desmopressin, as a “designer‐drug,” in the treatment of overactive bladder syndrome

Hashim, Hashim; Malmberg, Lars‐Erik; Graugaard-Jensen, Charlotte; Abrams, Paul

doi:10.1002/nau.20613

Cited by 35 publications

(27 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some recent studies have reported the efficacy of desmopressin in patients with OAB [10,11]. The rationale for use of desmopressin in the treatment of OAB patients is that through a decrease in urine production, desmopressin will increase the time taken to reach functional bladder capacity between daytime voids, thereby reducing frequency and urgency and benefiting adults suffering from OAB.…”

Section: Discussionmentioning

confidence: 99%

“…Several recent clinical trials have reported promising results showing improvement of symptoms of daytime frequency and urgency in patients with OAB with desmopressin through decreases in renal urine production and increases in bladder filling time [10,11]. However, there have been no reports concerning the effect of desmopressin combined with anticholinergics.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder

Han

Lee

et al. 2011

Korean J Urol

View full text Add to dashboard Cite

PurposeThe aim of this study was to evaluate the effect of desmopressin combined with anticholinergics on daytime frequency and urgency in female patients with overactive bladder (OAB).Materials and MethodsWe included 68 female patients with OAB. Patients were randomly assigned to receive 5 mg of solifenacin (group I) or 5 mg of solifenacin and 0.2 mg of desmopressin (group II) for 2 weeks. A pre/post-treatment 3-day voiding diary and the Urinary Distress Inventory (UDI-6) and Incontinence Impact Questionnaire (IIQ-7) were used to assess changes in voiding symptoms and quality of life (QoL); results were compared between the two groups.ResultsGroups I and II included 31 and 37 patients, respectively. Time to first void was 12 min later in group II (105 min vs. 117 min), but this difference was not statistically significant. However, time to the second and third voids (203 min vs. 255 min, 312 min vs. 368 min) and the first urgency episode (212 min vs. 255 min) were significantly longer in group II. Compared with group I, patients in group II showed significant improvement in QoL scores. When improvement after treatment was defined as increase in time to first void of greater than 10% after 2 weeks of treatment, desmopressin with anticholinergics was more effective in patients over the age of 65 years and with more than 150 ml of voided volume.ConclusionsDesmopressin combined with anticholinergics was more effective than anticholinergics only in the treatment of female patients with OAB.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder

Han

Lee

et al. 2011

Korean J Urol

View full text Add to dashboard Cite

show abstract

“…It is thought that DDAVP, a vasopressin analog, prolongs bladder filling time thereby increasing the time to reach maximum capacity; this increases time between voids, allowing patients to remain dry though the night [4,22]. It is generally considered first-line therapy for enuresis due to its rapid onset and efficacy.…”

Section: Discussionmentioning

confidence: 99%

A retrospective observational study of enuresis, daytime voiding symptoms, and response to medical therapy in children with attention deficit hyperactivity disorder and autism spectrum disorder

Gor

Fuhrer

Schober

2012

Journal of Pediatric Urology

View full text Add to dashboard Cite

“…A proof-of-concept, double-blind, placebo-controlled, randomized, cross-over study included 88 adult patients with OAB. 14 The investigators reported that treatment with desmopressin 0.2 mg was associated with a significant reduction in the number of voids over eight hours (3.2 vs. 4.2; p < 0.001). There was also a significant increase in the time to first urgency episode and a decrease in the number of urgency episodes for desmopressin compared to placebo (p < 0.003).…”

Section: Desmopressinmentioning

confidence: 99%

Systematic review of overactive bladder therapy in females

Cardozo

2013

CUAJ

View full text Add to dashboard Cite

Although the prevalence of overactive bladder (OAB) is similar in both male and female populations, females have a greater tendency to seek medical advice regarding their symptoms. A review of the evidence of therapy among women shows that a variety of modalities has been shown to be effective for symptom improvement in women with OAB. Bladder retraining/re-education should be considered for all women with OAB. With respect to first-line pharmacotherapy with antimuscarinic agents, the development of extended release preparations, bladder selective M3 antagonists and alternative routes of delivery, have improved compliance and persistence. Other pharmacotherapeutic options with potential for providing benefit include antidepressants, vasopressin analogues, alpha-adrenoceptor antagonists and beta-adrenoceptor agonists. There are also a number of newer agents currently being investigated, including calcium channel blocking agents, potassium channel opening drugs, beta agonists and neurokinin receptor antagonists. Intravesical injections of botulinum toxin may be an alternative, while surgery can be considered for truly intractable cases.

show abstract

Desmopressin, as a “designer‐drug,” in the treatment of overactive bladder syndrome

Abstract: Antidiuresis, using oral desmopressin tablets, is a novel, feasible and safe (short-term basis) method of treatment for adults with OAB, and could be considered in the armamentarium of drugs available for the treatment of OAB.

Cited by 35 publications

References 22 publications

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder

Effect of Desmopressin with Anticholinergics in Female Patients with Overactive Bladder

A retrospective observational study of enuresis, daytime voiding symptoms, and response to medical therapy in children with attention deficit hyperactivity disorder and autism spectrum disorder

Systematic review of overactive bladder therapy in females

Contact Info

Product

Resources

About